2seventy bio Inc (TSVT)
5.10
+0.15
(+3.03%)
USD |
NASDAQ |
May 07, 12:46
2seventy bio Research and Development Expense (Quarterly): 51.22M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 51.22M |
September 30, 2023 | 51.32M |
June 30, 2023 | 59.98M |
March 31, 2023 | 68.25M |
December 31, 2022 | 60.14M |
September 30, 2022 | 58.16M |
June 30, 2022 | 64.56M |
Date | Value |
---|---|
March 31, 2022 | 65.88M |
December 31, 2021 | 50.22M |
September 30, 2021 | 61.13M |
June 30, 2021 | 63.69M |
March 31, 2021 | 77.57M |
December 31, 2020 | 68.88M |
September 30, 2020 | 72.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
50.22M
Minimum
Dec 2021
77.57M
Maximum
Mar 2021
62.37M
Average
62.41M
Median
Research and Development Expense (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 2.695B |
Johnson & Johnson | 3.542B |
Macrogenics Inc | 47.35M |
Akebia Therapeutics Inc | 9.865M |
Tango Therapeutics Inc | 31.34M |